- About Us
- About MS
- Teen Adventure Camp
- Contact Us
The authors studied the tolerability of subcutaneous interferon beta-1a (IFN-1a) in 51 patients with early-onset multiple sclerosis. The most frequent systemic adverse effects were flu-like symptoms in 65%. Laboratory abnormalities included asymptomatic leukopenia (27%) and elevated hepatic transaminases (35%). Treatment with IFN-1a was safe and well tolerated in the majority of children and adolescents.
Stony Brook University Hospital
101 Nicolls Road Stony Brook, NY 11794